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RESUMO 
O Linfoma difuso de grandes células B (LDGCB) é o subtipo mais comum dos 
Linfomas Não-Hodgkin, correspondendo a cerca de 30% a 40% de novos casos e a mais 
de 80% dos linfomas agressivos. Devido à sua heterogeneidade clínica, morfológica, 
imunológica e genética, torna-se pertinente, aquando do diagnóstico, identificar os doentes 
que irão beneficiar da administração de um tratamento mais agressivo. O sistema de 
classificação segundo o estadio Ann Arbour, não é, por si só, suficiente, sendo necessário 
a utilização do Índice Internacional de Prognóstico como ferramenta mais completa. No 
entanto, têm surgido novos marcadores de prognóstico. Assim, torna-se essencial um 
melhor conhecimento das alterações epigenéticas, que constituem o alvo do presente 
estudo, para a aplicação de decisões terapêuticas ajustadas e personalizadas na tentativa 
de obter melhores resultados clínicos 
Neste estudo, tivemos por objetivo avaliar a expressão das modificações 
epigenéticas pós-traducionais das histonas H3K4me3 (trimetilação da lisina 4 da histona 
H3) e H3K27me3 (trimetilação da lisina 27 da histona H3), correlacionando-as com os 
parâmetros clínicos e patológicos, determinando o seu potencial como biomarcadores de 
prognóstico em LDGCB. 
Com este propósito, foi realizado um estudo transversal retrospetivo baseado em 
155 casos de Linfoma difuso de grandes células B consecutivamente diagnosticados e 
tratados no Instituto Português de Oncologia do Porto, entre 2008 e 2013, do qual existia 
material biológico de arquivo disponível para avaliação da imunoexpressão das marcas 
epigenéticas H3K4me3 e H3K27me3, utilizando um sistema de quantificação baseado em 
análise de imagem digital para determinar os parâmetros “percentagem de células 
positivas” e o “Hscore”.  Foi utilizada a base de dados do Serviço de Oncohematologia para 
obtenção dos parâmetros clínicos e patológicos relevantes. 
Com base na análise da sobrevivência, o sistema de classificação Ann Arbour 
agrupado (p=0.015), o IPI agrupado (p=0.041) e a idade quando o diagnóstico (≤ ou > 60 
anos e ≤ ou > 70 anos, p=0.006 e p=0.005, respetivamente) foram confirmados como 
fatores de prognóstico. Na avaliação das marcas epigenéticas H3K4me3 e H3K27me3, 
não se observou associação com a sobrevivência global nem com a sobrevivência livre de 
doença, embora se tenha identificado uma associação entre o IPI (p=0.41) e a marca 
epigenética H3K27me3. 
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A coorte de pacientes estudados é globalmente representativa dos casos de 
LDGBCB, conforme atestado pela verificação da associação entre diversos parâmetros 
clínicos e o prognóstico. Contudo, as marcas epigenéticas H3K4me3 e H3K27me3 não 
revelaram valor prognóstico nesta neoplasia. Fatores como a dimensão da amostra e a 
ausência de categorização de acordo com a célula de origem poderão contribuir para 
explicar este resultado negativo. Assim, será necessário incrementar a série e melhor 
caracterizá-la imunofenotipicamente para concluir mais definitivamente sobre o potencial 
valor clínico deste biomarcadores epigenéticos. 
 
Palavras-Chave: Linfoma não Hodgkin, linfoma difuso de grandes células B, epigenética, 
biomarcadores, Imunocitoquímica, prognóstico. 
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SUMMARY 
Diffuse large B-cell lymphoma (DLBCL), a heterogenous category of aggressive 
lymphoid malignancies, is the most common type of B-cell non-Hodgkin lymphoma, 
accounting for approximately 30 to 40% of all newly diagnosed cases worldwide and 80% 
of aggressive lymphomas. The DLBCL lymphomagenesis remains complex and mostly 
unknown. Prognostic information for most NHL is not accurately provided by the Ann Arbour 
system and it is of limited value for treatment decisions. International Prognostic Index (IPI) 
and R-IPI remain the most reliable tools for predicting outcome in patients with DLBCL. 
Additional prognostic markers are under investigation. Epigenetic changes are now 
recognized as playing an important and early role in the lymphomagenesis process, 
contributing to the disease progression. 
In this study, we aimed to quantitatively evaluate the expression of the post-
translational epigenetic modification of H3K4me3 (trimethylation of lysine 4 on histone H3) 
and H3K27me3 (trimethylation of lysine 27 of histone 3) in a series of diffuse large B-cell 
lymphoma through immunoexpression and correlation with clinicopathological parameters, 
to determine its relevance as prognostic biomarker. 
A retrospective transversal study was performed using archival biological material 
from 155 patients with diffuse large B-cell lymphoma, consecutively diagnosed and treated 
between 2008 and 2013 at the Portuguese Oncology Institute of Porto. The H3K4me3 and 
H3K27me3 marks were assessed by immunohistochemistry, using a digital imaging 
assisted system to determine the % of positively immunostained cells and the Hscore. 
Relevant clinical and pathological data was extracted from the database of the Department 
of Oncohematology.  
In this study, grouped Ann Arbour stage (p=0.015), grouped IPI score (p=0.041) and 
age at the time of diagnosis (≤ or > 60 years and ≤ or > 70 years, p=0.006 and p=0.005, 
respectively) were all significantly associated with prognosis. Quantitative H3K4me3 and 
H3K27me3 imnunoexpression did not associate with overall or disease-specific survival, 
although a significant association between IPI score and H3K27me3 mark was disclosed 
(p = 0.041). 
Our patient cohort is globally representative of DLBCL patients as depicted by the 
significant associations between established prognostic parameters and patient outcome. 
Nevertheless, H3K4me3 and H3K27me3 immunoexpression were not shown to display 
prognostic value in this dataset. This negative result might be partially explained by 
insufficient sample size and lack of discrimination of DLBCL subtypes according to cell of 
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origin. Thus larger studies, with increased sample size to provide a more robust statistical 
analysis and additional immunophenotyping for DLBCL subtyping are required to more 
conclusively determine whether H3K4me3 and H3K27me3 might be of prognostic value in 
DLBCL. 
 
Keywords: Diffuse large B-cell lymphoma, epigenetics, molecular biomarkers, non-
Hodgkin lymphoma, immunohistochemistry, H3K4me3, H3K27me3, prognosis. 
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Lymphoma is the malignant neoplasm from lymphoid system cells. It is 
predominantly located in the lymph nodes or other extra lymph node location, such as 
spleen, bone marrow, skin, gastrointestinal tract and other organs (1,2). The World Health 
Organization (WHO) classifies lymphomas into two major groups, comprising Hodgkin's 
Lymphomas (LH) and Non-Hodgkin's Lymphomas (NHL). Hodgkin lymphoma and Non-
Hodgkin lymphoma can be differentiated pathologically, by its pattern of disease, treatment 
and prognosis (2).  
Non-Hodgkin’s Lymphomas are a heterogeneous group of diseases that originate 
from mature and immature B, T or Natural Killer (NK) cells (2), representing 4% of all cancers, 
which are more frequent in developed countries, such as United States of America (EUA), 
Australia and Western Europe (2,3) (Figure 1).  
 
In Western Europe, the estimated incidence in 2012 was 34,188 new cases, 
accounting for 3.1% of all diagnosed cancers (Figure 2) (3). The same trend was reported 
for Portugal, in which the estimated incidence rate, for the same year, was 1,842 new cases, 
accounting for 3.7% of all cancers (Figure 2) (3). 
 
  
 o Data
  .6
 .6  . 
 .   . 
 .  7.0
7.0 
 on Hodgkin lymphoma
Source  GL    A   0    IAR  
Incidence ASR
 oth se es
Figure 1- Estimated age-standardized incidence rates of NHL per 100,000, worldwide. Adapted from (3). 
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In 2016, the WHO classification of hematopoietic and lymphoid tumours was revised 
(4)
. Although alterations are limited compared with the 2008 version, it will include a large 
set of information published over the last 8 years with significant diagnostic, prognostic and 
therapeutic implications (4). The updated classification of the mature B-cell neoplasms is 
depicted in Table 1 and constitutes the worldwide gold standard. 
 
Table 1 – 2016 WHO classification of Mature B-Cell, T and NK neoplasms. Adapted from (4). 
Mature B-cell neoplasm 
Chronic lymphocytic leukemia/small lymphocytic lymphoma 
Monoclonal B-cell lymphocytosis* 
B-cell prolymphocytic leukemia 
Splenic marginal zone lymphoma 
Hairy cell leukemia 
Splenic B-cell lymphoma/leukemia, unclassifiable 
• Splenic diffuse red pulp small B-cell lymphoma 
• Hairy cell leukemia-variant 
Lymphoplasmacytic lymphoma 
• Waldenström macroglobulemia 
Monoclonal gammopathy of undetermined significance(MGUS), IgM* 
µ heavy-chain disease 
γ heavy-chain disease 
α heavy-chain disease 
Monoclonal gammopathy of undetermined significance(MGUS), IgG/A* 
  
Figure 2 - Estimated incidence of distinct types of cancer in Western Europe and Portugal in 2012, number of 
newly diagnosed cases and proportion of each cancer comparing to all types of cancer (in both genders, 
excluding non-melanoma skin cancers). Adapted from (3). 
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Table 1- (continued) 
Plasma cell myeloma 
Solitary plasmacytoma of bone 
Extraosseous plasmacytoma 
Monoclonal immunoglobulin deposition diseases* 
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 
Nodal marginal zone lymphoma 
• Pediatric nodal marginal zone lymphoma 
Follicular lymphoma 
• In situ follicular lymphoma* 
• Duodenal-type follicular lymphoma* 
Pediatric-type follicular lymphoma* 
Large B-cell lymphoma with IRF4 rearrangement* 
Primary cutaneous follicle center lymphoma 
Mantle cell lymphoma 
• In situ mantle cell neoplasia* 
Diffuse large B-cell lymphoma (DLBCL), NOS 
• Germinal center B-cell Type* 
• Activated B-cell type* 
T-cell/Histiocyte-rich large B-cell lymphoma 
Primary DLBCL of the central nervous system (CNS) 
Primary cutaneous DLBCL, leg type 
EBV+ DLBCL, NOS* 
EBV+ mucocutaneous ulcer* 
DLBCL associated with chronic inflammation 
Lymphomatoid granulomatosis 
Primary mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
ALK+ large B-cell lymphoma 
Plasmablastic lymphoma 
Primary effusion lymphoma 
HHV8+ DLBCL, NOS* 
Burkitt lymphoma 
Burkitt-like lymphoma with 11q aberration* 
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements* 
High-grade B-cell lymphoma, NOS* 
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma 
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Table 1- (continued) 
Mature T and NK neoplasms 
T-cell prolymphocytic leukemia 
T-cell large granular lymphocytic leukemia 
Chronic lymphoproliferative disorder of NK cells 
Aggressive NK-cell leukemia 
Systemic EBV+ T-cell lymphoma of childhood* 
Hydroa vacciniforme-like lymphoproliferative disorder* 
Adult T-cell leukemia/lymphoma 
Extranodal NK/T-cell lymphoma, nasal type 
Enteropathy-associated T-cell lymphoma 
Monomorphic apitheliotropic intestinal T-cell lymphoma* 
Indolent T-cell lymphoproliferative disorder of the GI tract* 
Hepatosplenic T-cell lymphoma 
Subcutaneous panniculitis-like T-cell lymphoma 
Mycosis fungoides 
Sézary syndrome 
Primary cutaneous CD30+ T-cell lymphoproliferative disorders 
• Lymphomatois papulosis 
• Primary cutaneous anaplastic large cell lymphoma 
Primary cutaneous γδ T-cell lymphoma 
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma 
Primary cutaneous acral CD8+ T-cell lymphoma 
Primary cutaneous acral CD4+ small/medium T-cell lymphoproliferative disorder* 
Peripheral T-cell lymphoma* 
Angioimmunoblastic T-cell lymphoma 
Follicular T-cell lymphoma* 
Nodal peripheral T-cell lymphoma with TFH phenotype* 
Anaplastic large-cell lymphoma, ALK+ 
Anaplastic large-cell lymphoma, ALK-* 
Breast implant-associated anaplastic large-cell lymphoma* 
Italics - Provisional entities/ *Changes from the 2008 classification.  
 
In this Dissertation, the focus will be on a specific type of the NHL, the Diffuse Large 
B-Cell Lymphomas (DLBCL), which will be characterized in the next sections. 
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1 - DIFFUSE LARGE B-CELL LYMPHOMA 
1.1 - Epidemiology and Etiology 
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous category of aggressive 
lymphoid malignancies and represents the most common type of B-cell NHL, accounting 
for approximately 30% to 40% of all newly diagnosed cases worldwide (5,6,7,8). Given the 
aggressiveness of this disease, more than 50% of patients may be cured by current 
immune-chemotherapy protocols (5,9,10). The International Classification of Diseases for 
Oncology (ICD-O) is used to code malignant tumours using a coherent system and ICD-O 
code for DLBCL is 9680/3 (1). DLBCL lymphoma may affect patients of all ages but are 
mostly diagnosed in the elderly. The median age is at 60-70 years but it may occur in 
children and young adults as well (11,12,13). DLBCL is slightly more common in men than in 
women (1,2) with a M/F ratio of 1.7:1(14).  
The lymphomagenesis of DLBCL remains complex and mostly unknown. It can arise 
de novo, i.e., as a primary lymphoma but it may also derive from progression or 
transformation of a less aggressive (clinically indolent) lymphoma. There is a diversity of 
factors that may be involved on lymphomagenesis such as immunosuppression (significant 
risk factor), infectious agents (including human immunodeficiency virus - HIV, human 
herpes virus 8 - HHV8 and Helicobacter pylori - HP), toxicity from cytotoxic drugs and 
tumour biology (1, 2, 15). 
 
1.2 - Sites of involvement and clinical features. 
Patients may present nodal and/or extranodal disease. The most common 
extranodal sites are gastrointestinal tract, bone, head and neck, liver, kidney and thyroid (1, 
16)
. Nearly 10% to 25% of patients with DLBCL disease disclose bone marrow involvement 
(17, 18, 19)
. 
The clinical manifestations of DLBCL are diverse and depend on the site of disease 
involvement. Patients usually present with rapidly growing masses, causing some 
symptoms, but usually patients are asymptomatic (1).  
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1.3 - Morphology 
DL  L is characterize by   lymphoid cells with “nuclear size equal to or exceeding 
normal macrophage nuclei or more than twice the size of a normal lymphocyte, that has a 
diffuse growth pattern” (1) (Figure 3). 
 
 
 
 
 
 
  
It is divided into morphological variants, molecular and immunophenotypically 
subgroups and different disease entities (1). The heterogeneity of some cases make it 
impossible sometimes to include them on the previously defined subgroups, and these are 
classified as DLBCL, not otherwise specified (NOS). Thus, DLBCL, NOS includes al DLBCL 
cases that not fill in the specific subgroups mentioned above (1). 
 
1.3.1 -   Morphological variants 
 There are three morphological variants recognized (1): 
• Centroblastic variant – predominantly composed of centroblasts which 
“are medium-sized to large lymphoid cells with oval to round, vesicular 
nuclei containing fine chromatin”. It may contain two to four nuclear 
membrane-bound nucleoli. The cytoplasm is frequently scanty and 
amphophilic to basophilic. Frequently the tumour is polymorphic with an 
admixture of centroblasts and immunoblasts (<90%). This is the most 
common variant. 
Figure 3 – Diffuse large B-cell lymphoma typical cells (Hematoxylin 
and Eosin stain-H&E, case 286. Source: Department of Pathology, 
IPO PORTO. 
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• Immunoblastic variant – in which “greater than 90% of the cells are 
immunoblasts with a single centrally located nucleolus and an 
appreciable amount of basophilic cytoplasm”. 
• Anaplastic variant - characterized by “large to very large round, oval or 
polygonal cells with bizarre pleomorphic nuclei”. 
 
 
1.3.2 - Molecular subgroups 
Based on similarities to the cell of origin (COO), DLBCL can be subdivided into three 
subtypes: the germinal center B-cell like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL 
and primary mediastinal large B-cell lymphoma (PMBCL) (1,5,6,9). This classification includes 
gene alterations and drug sensitivities. 
GCB cells are produced from mature B cells in lymphoid organs that have been 
activated by interactions with an antigen and T-helper cells. The differentiation on GCB cells 
activates somatic hypermutation, leading to diversity in the immunoglobulin gene regions 
(5,20)
. ABC DLBCL has a gene expression feature identical to plasma cells, arise from post 
germinal center B cells that are arrested during plasmocytic differentiation (5,20). Primary 
mediastinal large B-cell lymphoma presents with mediastinal lymphadenopathy and has 
some molecular genetic similarities with Hodgkin lymphoma (5, 20). 
By next-generation sequencing techniques it was found that alterations of chromatin 
remodelling genes are predominant in GCB subtype, whereas gene mutations of B-cell 
receptor (BCR) signalling and NF-kB pathway are frequent in ABC subtype (6). The ABC 
DLBCL subgroup has a poorer overall survival compared to GCG DLBCL subgroup (5,6). 
 
 
1.3.3 - Immunophenotypical subgroups 
Immunohistochemical staining is used to make an approximation to the cell-of-origin 
subtype of DLBCL. It allows for the discrimination of GCB from non-GCB subgroups. The 
Hans algorithm (9) which uses the antibodies CD10, BCL6, and IRF4, also called MUM1 
(21,22,23)
, is the most widely used (Figure 4 and 5). 
 
Epigenetic biomarkers in Diffuse large B-cell lymphoma 
 
 10 
 
      
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Hans algorithm based on the immunohistochemical analysis of three markers 
(CD10, Mum1 and bcl6). Adapted from (9). 
CD10 
Bcl-6 
GCB 
MUM-1 
Non-GCB 
Non-GCB 
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+ 
- 
+ 
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- 
Figure 5 - Example of immunohistochemical staining for DLBCL. Case 286: CD10 -, BCL6-, MUM1 +, a Non-
GCB subtype. Source: Department of Pathology, IPO Porto. 
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1.4 - Staging 
 Choosing the most appropriate therapy involves accurate diagnosis and careful 
staging evaluation. The first staging concept was developed during the 20th century in the 
United States. Disease heterogeneity was a challenge for development of a uniform staging 
system. The first staging system was named Ann Arbour Staging System and it was used 
for Hodgkin lymphomas, but it was later modified and adapted for NHL, providing an 
anatomic staging (24). 
 The Ann Arbour Staging System divides patients into four stages, depending on 
whether it is localized disease, multiples sites of disease on one or the other side of the 
diaphragm, lymphatic disease on both sides of diaphragm and disseminated extranodal 
disease (1, 24) (Table 2). 
 
Table 2 – Ann Arbour Classification. Adapted from (24). 
Stage Features 
I Involvement of a single lymph node region or lymphoid structure (e.g. spleen, thymus, Waldeyer’s 
ring) 
II Involvement of two or more lymph node regions on the same side of diaphragm 
III Involvement of lymph node regions on both side of diaphragm 
IV Involvement of extranodal site(s) beyond that designated E 
For all stages 
A No symptoms 
B Fever (>38ºC), drenching sweats, weight loss (10% body weight over 6 months) 
For Stages I to III 
E Involvement of a single, extranodal site contiguous or proximal to known nodal site 
 
 
1.5 - Prognosis 
Prognostic information for most NHL is not accurately provided by the Ann Arbour 
system and it is of limited value for treatment decisions (24). 
In 1993, the International Prognostic Index (IPI) (25) was developed as a primary 
clinical tool to predict outcome in patients with aggressive NHL (26). This classification is 
based on some negative prognostic factors at the time of diagnosis (Table 3). It includes 
age over 60 years, Eastern Cooperative Oncology Group (ECOG) poor performance status 
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(Table 4), Ann Arbour Stage I and II versus Stage III or IV, elevated serum lactate 
dehydrogenase (LDH) and involvement of two or more extranodal sites as high-risk factors 
(24, 25, 26)
. 
 
Table 3 – International Prognostic Index. Adapted from (1,24). 
Prognostic Factors Risk Category Factors 
• Age > 60 years 
• Performance status > 2 
• Lactate dehydrogenase 1x normal 
• Extranodal sites > 2 
• Stage III or IV 
 
• Low (0 or 1) 
• Low-intermediate (2) 
• High-intermediate (3) 
• High (4 or 5) 
 
Table 4 – Eastern Cooperative Oncology Group Performance Status. Adapted from (24, 28). 
Grade Description 
0 Fully active, able to carry on all predisease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature (eg, office work) 
2 Ambulatory and capable of self-care but unable to carry out any work activities. Up and about 
more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 
5 Dead 
 
The IPI stratified DLBCL into four discrete outcome groups with a 5-year overall 
survival (OS) ranging from 26 to 73% (25,26, 27). Further studies demonstrated that a better 
risk discrimination was achieved with a re-categorized IPI (R-IPI) for rituximab-based 
immunochemotherapy (26). Thus, Sehn et al stratified IPI into three categories with 
significantly different outcome:  
• “Very good”  score 0  – patients with zero risk factors, with more than 90% 
chance of long-term progression-free survival 
• “Good”    or    – patients with one or two risk factors, with approximately 
80% chance of long-term progression-free survival 
• “Poor”  3-5) – patients with three, four or five risk factors, with a 50% chance 
of long-term progression-free survival. 
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Risk group with less than 50% likelihood of long-term progression-free survival is 
not identified by neither IPI or R-IPI (26).  
Many studies have subsequently focused on recognizing novel molecular and 
genetic markers to define more precise prognostic factors. Although several molecular 
prognostic markers have been identified, they have still not been validated (29,30,31). Thus, 
IPI and R-IPI remain the most reliable tools for predicting outcome in patients with DLBCL 
(26)
, and it is recommended that evaluation of a new patient should involve both systems: 
Ann Arbour Staging and International Prognostic Index. 
 
1.6 – Therapy 
 Although DLBCL are very aggressive, they are potentially curable with multimodal 
chemotherapy (1). The cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone 
(CHOP) chemotherapy regimen has been considered the standard treatment for several 
decades (32). In 1994, the results from Czuczman et al encouraged the use of rituximab with 
CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone - R-
CHOP) for indolent lymphoma (34). Subsequently, improved failure-free survival (FFS) and 
OS with R-CHOP (administered as rituximab on day 1 of each of eight CHOP cycles) 
compared with CHOP, especially in older patients, was disclosed (32, 35, 36). Thus, R-CHOP 
is currently the standard of care in treatment of older patients with DLBCL. Toxicity data 
and efficacy associated with the number of chemotherapy cycles and the number of 
rituximab infusions must, however, be considered (7,32,33). Nevertheless, about 35% to 50% 
of patients with advanced-stage disease are not cured using R-CHOP (8). Therefore, it is 
important to understand and make efforts to identify biologic subgroups among DLBCL and 
develop more appropriate treatments to address DLBCL heterogeneity (32). 
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2 – EPIGENETICS 
“Epigenetics”, a term firstly used by Conrad Waddington (37,87), consist on the study 
of heritable changes in gene expression, involving active and inactive genes, without 
change in the DNA sequence. There is a change in phenotype without a change in genotype 
(39, 40, 41)
. Epigenetic change is a regular and natural occurrence but can also be influenced 
by several factors including age and the environment/lifestyle (40). Epigenetic change can 
induce damaging effects, helping the cell to adapt or promoting pathological behaviour, that 
can result in cancer formation. It may occur at distinct stages of tumorigenesis and 
contribute to the development or progression of cancer. There is variable heterogeneity in 
epigenetic alterations that may give similar phenotypes. Thus, the varied clinical behaviour 
of cancers can range from indolent, slow-growing to aggressive, fast-growing tumors (41). 
The epigenetic mechanism embrace three main systems: DNA methylation, histone 
modification and non-coding RNA (ncRNA)-associated gene silencing, that are currently 
considered to initiate and sustain epigenetic change (40). 
 
2.1 – DNA Methylation 
DNA methylation is one of the most well studied and characterized epigenetic 
modifications, which consists on the addition of a methyl group to carbon 5 of the cytosine 
residue within the nucleotide cytosine-phosphatidyl-guanine (CpG) (43, 44) (Figure 6). CpG 
methylation of DNA is found at sites with a high percentage of CpGs (so-called CpG 
islands), leading to transcriptional repression (40). 
 
De novo methylation marks are established by DNA methyltransferase (DNMT) 3a 
and 3b, through embryonic development. The formation of heterochromatin and gene 
Figure 6 – DNA methylation. DNA gets methylated at the pyrimidine ring of the cytosine. The methyl mark leads 
to changes in the chromatin structure and recruits effector molecules. (A-adenosine; C-cytosine; G-guanine; T-
thymine). Adapted from (40). 
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silencing depends on DNA methylation (40, 44). In almost all forms of cancer aberrant 
hypermethylation and silencing of tumor suppressor genes has been found. Both 
hypometylation and hypomethylation of CpG islands located at gene promoters may affect 
the expression of protein coding genes and of non-coding R A’s, eventually resulting in 
tumorigenesis (44-47). 
 
2.2 – Histone modification  
The second major mechanism in epigenetic gene regulation is modification of 
histone tails by chromatin modifying enzymes, that has significant impact on intra and inter-
nucleossomal interactions (44,48,49,50). DNA is packaged around an octamer comprising 
homodimers of four different histone proteins: H2A, H2B, H3 and H4. The nucleosome is 
stabilized in place by H1. Every histone protein has an N-terminal tail, which is the main 
target of a diversity of histone modifications (40) (Figure 7). 
 
  
 
 
Modifications of histones can make changes into two ways: modifications can be 
recognized by “readers” that can recruit additional factors like other chromatin-modifying 
enzymes, and acetylation and phosphorylation may act on chromatin structure by reducing 
Figure 7 -Function of chromatin modifying and organizing genes. DNA is wrapped around histone octamers to 
form a nucleosome. Adapted from (50). 
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the positive charge of histones and alter their association with negatively charged DNA (51-
55)
. 
2.2.1 – Histone lysine methylation 
Histone lysine methylation may occur at residues 4, 9, 27, 36 and 79 of Histone 3 
and residue 20 of Histone 4 (56). Three degrees of methylation are known: mono-methylation 
(me1), di-methylation (me2) or trimethylation (me3) that may be associated with active 
euchromatin or inactive heterochromatin states (40,57). H3K4 methylation is frequently 
associated with active transcription and, thus, H3K4me3 is usually located around promotor 
regions whereas H3K4me1 is located around enhancer regions. In contrast to H3K4me3, 
trimethylation of lysine 27 on histone H3 (H3K27me3) is associated with transcriptional 
repression. Histone methylation does not have a direct effect on chromatin structure (57-59). 
Histone lysine methylation is also a dynamic process that encodes a diversity of 
chromatin states (40). 
➢ H3K4 methylation 
One of four members in the mixed lineage leukemia (MLL) family proteins - 
KMT2D (MLL2) – is involved in H3K4 methylation. KMT2D somatic mutations 
are found in most follicular lymphomas (FL) but is less common in GCB-like 
DLBCL. The polycomb repressor complex 2 is unable to methylate H3K27me3 
if H3K4 is trimethylated in the same histone tail. The H3K4me3 is recognized by 
reader proteins such as the product of ING1 gene, which is deleted in 1/3 of 
GCB-like DLBCL. Until now, there is no evidence of the effect of KMT2D 
mutation on H3K4 methylation or a suggestion of the mechanism by which these 
mutations promote lymphomagenesis (40,51,60). 
➢ H3K27 methylation 
Enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of an epigenetic 
gene-silencing complex named polycomb repressive complex 2 (PRC2). It is a 
SET domain histone methyltransferase that catalyses histone 3 lysine 
27(H3K27) methylation, leading to a transcriptional repression of the target gene 
(50, 57, 61-67)
. 
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Components of PRC2 are highly expressed in germinal centers. The first 
chromatin-modifying gene alteration described in DLBCL was EZH2 mutation. An 
increase or decrease of H3K27 methylation activity may lead to malignancy, 
depending on the cell of origin of the tumor (57, 67-69).  The H3K27me3 mark is self-
sustaining, as DNA replicates, H3K27 methylated histones recruits PRC2 and 
PRC1 complexes to nucleosomes of the nascent DNA strand to continue gene 
silencing (70). Heterozygous EZH2 mutations suggest that cancer cells were 
haploinsufficent for the enzymatic activity. It can result in deficient H3K27 
methylation and widespread derepression of gene expression. Overexpression 
of EZH2 may cause silencing of growth-suppressive genes (71). Some studies 
propose that increased or decreased H3K27methylation activity may lead to 
malignancy, depending on the cell of origin (72,73, 74). 
 
Figure 8 – Deregulation of H3H27 methylation 
in cancer. A – EZH2 trimetylates H3K27 to 
inhibit gene expression; loss of EZH2 in cancer 
may lead to derepression of genes that 
promote cell growth. B – EZH2 overexpression 
silences additional targets. C-UTX removes 
H3K27me3 marks, loss of UTX increases 
H3K27me3 and silences tumor suppressors. 
Adapted from (57).  
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2.3 – Epigenetics of diffuse large B-cell lymphoma 
 Complex diseases require clarifications about genetic and environmental influences 
in the causative factors and prediction parameters. Epigenetic code alterations have been 
found in diverse pathological conditions (55,75), including cancer (76). In DLBCL, it was 
demonstrated that EZH2 is important for G2/S transition and represses cell cycle-related 
tumor suppressor genes, through trimethylation of H3K27, contributing disease progression 
(77)
. Mutations of EZH3 were identified in 22% of GCB DLBCL (55, 58, 64, 68). The most frequent 
EZH2 mutations are found in the SET domain of EZH2 affecting tyrosine 641 (Y641), 
alanine 677 (A677) and alanine 687 (A687). EZH2 gain-of-function mutations favours 
increased H3K27me3 levels and loss-of-function mutations were identified in H3K4 
trimethylase MLL2 in 32% of DLBCL (80,81). Whereas H3K27 trimethylation due to EZH2 
activity has been associated with gene repression, methylation of H3K4 was associated 
with gene expression, with MLL and EZH2 displaying opposite functions (82). Indeed, 
elevated levels of H3K27me3 in approximately one third of the DLBCL cases has been 
reported, suggesting that it may be involved in a subgroup of DLBCL. Moreover, an elevated 
level of H3K27me3 was associated with poor overall survival within non-GCB DLBCL 
patients (83).
  
 
 
 
 
 
 
 
 
 
 
 
 
AIMS OF THE STUDY
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As previously stated, altered activity of MLL and EZH2 has been reported in DLBC 
lymphoma, affecting the levels of the respective marks, H3K4me3 and H3K27me3, 
eventually causing altered expression of several critical genes. Thus, we hypothesized that 
quantitative evaluation of H3K4me3 and H3K27me3 might constitute biomarkers of DLBC 
progression, providing novel prognostic parameters for risk stratification of patients with 
DLBCL. 
Hence, the specific aims of this Dissertation are: 
 
- To evaluate quantitatively the immunohistochemical expression of histone-marks 
H3K4me3 and H3K27me3 in diffuse large B-cell lymphoma; 
 
- To correlate the immunohistochemical expression with standard histopathological 
and clinical parameters, as well as disease-specific and overall survival; 
 
- To verify their potential value as prognostic biomarkers for patients with diffuse large 
B-cell lymphoma. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS
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1 - PATIENTS AND SAMPLES 
For the purposes of this retrospective study, patients diagnosed (Department of 
Pathology) and treated (Department of Onco-Hematology) for diffuse large B-cell lymphoma 
at Portuguese Oncology Institute of Porto, Portugal between 2008 and 2013 were identified. 
Then, all cases with available representative archived tissue were enrolled, corresponding 
to 155 patients. 
Pertinent clinical data were collected from the clinical charts by an experienced 
Hematologist (Dr. Sérgio Chacim) from the Department of Onco-Hematology. 
This study, the use of samples and access to clinical data were approved by the 
institutional review board (Comissão de Ética para a Saúde) of Portuguese Oncology 
Institute of Porto, Portugal. 
 
2 – IMMUNOHISTOCHEMISTRY 
Three µm thick paraffin sections were obtained from representative formalin-fixed 
paraffin embedded tissue from each case, and placed in positively charged slides 
(Histobond®, Marienfeld, Germany) for immunohistochemistry assays. 
For deparaffinization, slides were placed in an oven at 60ºC for 1 hour and 30 
minutes, and then immersed in xylene (Sigma-Aldrich®, St.  Louis, MO, USA). 
Subsequently, sections were hydrated in decreasing series of ethanol solutions (Merck, 
Darmstadt, Germany). 
 
2.1 - Epitope retrieval and endogenous peroxidase neutralizing 
 For antigens retrieval, slides were placed in sodium citrate buffer (1:100; pH6; 
Vector® Antigen Unmasking Solution; H-3300; Burlingame; CA 94010 U.S.A) in a Bosch 
microwave oven at 700W (2 cycles of 10 minutes each).  
Endogenous peroxidase activity was neutralized with 0.6% hydrogen peroxide for 
20 minutes (Merck). 
Protein detection was performed using the NovolinkTM Max Polymer Detection 
System (Leica Biosystems, Nussloch, Germany), according to a standard protocol (Annex 
1). Depending of the antibody used, the incubation period varied, as depicted in Table 5. 
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Table 5 – Antibodies and Conditions 
Antibodies Company Clone Positive 
Control 
Dilution Incubation 
 
H3H4me3 
 
Abcam 
Rabbit 
polyclonal-
ChIP Grade 
ab8580 
 
Hepatocellular 
carcinoma 
 
1:1000 
 
1h 
(Humid 
chamber) 
 
 
H3K27me3 
 
Cell Signaling 
Technology 
Rabbit 
monoclonal 
antibody 
(mAb) -
C36B11 
 
Colorectal 
cancer 
 
 
1:1500 
 
Overnight 
(4ºC – Humid 
chamber) 
  
 Successive washing steps were performed with tris buffered saline with Tween® 20 
(TBS-T) (Sigma-Aldrich®).  
Antigen-antibody binding reaction was revealed by means of incubation with a 
0.0 %  m/v  3,3’- diaminobenzidine (DAB) solution (Sigma-Aldrich®) in phosphate-buffered 
saline (PBS) (Biochrom Ltd., Cambridge, United Kingdom) previously activated with a 0,1% 
hydrogen peroxide solution, for 7 minutes, in the dark. 
Counterstaining of the slides was performed with hematoxylin (Merck) for 30 
seconds and then slides were washed for 1 minute in a tap water. 
Finally, slides were dehydrated in an increasing series of ethanol solutions, 
diaphanized in xylene and mounted. 
Negative control consisted on the omission of the primary antibody. Appropriate 
positive controls (see Table 5) were used in each batch. 
 Positive control slides were evaluated in an optical microscope by an experienced 
Pathologist.  
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3 - NUCLEAR IMMUNOSTAINING QUANTIFICATION 
 The nuclear immunostaining quantification was done by a digital image analysis 
system (GenASIs, Version 7. .7.3   0, ASI, “Applied Spectral Imaging”,  0 3  (Figure 9).  
 
 
The slides were scanned at 200x magnification and high-resolution digital images 
were obtained. Manual selection of 5 to 8 areas of tumour cells were captured to reach at 
least 5000 cells fit for evaluation (Figure 10).  
  
Figure 9 - Equipment support for the digital image analysis system GenASIs™. 
Figure 10 – Example of capture digital images on GenASIs™ software. 
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Subsequently, positive nuclei were automatically detected and a nuclear 
classification into 4 levels of intensity (0-3) was generated, each one identified with a 
different color (Figure 11):  
• 0 (negatively stained nuclei) – blue;  
• 1 (low intensity stained nuclei) – yellow;  
• 2 (intermediate intensity stained nuclei)– orange; 
• 3 (higher intensity stained nuclei) – red. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Example of nuclear classification into 4 levels of intensity on GenASIs™ software. 
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The percentage of immunostained nuclei and the H-score were determined for each 
case and used for subsequent analyses. 
 
 
4 - STATISTICAL ANALYSIS 
For statistical analysis, patients were divided into two Ann Arbour Stage groups 
(stage I/II, stage III/IV) and into three IPI scores (0/1-2/3-5). Cutoffs for H3K4me3 and 
H3K27me3 nuclear immunostaining (high vs. low) were set at 25th and 75th percentile (P25 
and P75). Comparison between % Positivity, Hscore, clinical and pathological parameters 
was performed using non-parametric tests (Mann-Whitney or Kruskall-Wallis, for IPI). 
Survival curves were created using Kaplan-Meier non-parametric estimator. Survival 
between groups was compared using Log-rank test. Statistical significance was considered 
when p-value was inferior to 0.05. All statistical analyses were performed using R version 
3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
RESULTS 
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1 – CLINICAL AND PATHOLOGICAL CHARACTERIZATION OF THE PATIENTS 
 For the purposes of this study, 155 patients diagnosed with DLBCL and treated at 
the Portuguese Oncology Institute of Porto, from 2008 to 2013 were included. The clinical 
and pathological characteristics of this cohort are shown in Table 6. In this cohort, 43.6% of 
patients were male, and the median age at diagnosis was 66 years. Recurrent/transformed 
disease was experienced by 40 % of the patients. 
 
Table 6 - Clinical and pathological characteristics of the patients 
 N % 
 
Gender 
Female 87 56,1% 
Male 68 43,9% 
 
Age at Diagnosis 
≤ 70 years 99 63,9% 
> 70 years 56 36,1% 
 
Ann Arbour Stage 
I/II 79 50,6%* 
III/IV 72 46,2%* 
 
IPI 
Low risk (0) 21 13,5%** 
Intermediate risk (1,2) 66 42,6%** 
High risk (3-5) 51 32,9%** 
*3,2% of patients has unknown Ann Arbour Stage information. 
** 11% of patients has unknown IPI information. 
 
2 –SURVIVAL ANALYSIS 
The follow-up time was determined at date of the last consultation and the median was 
55.4 months. The overall survival was estimated as 76.7% at 2 years and 68.1% at 5 years. 
The disease-specific survival was estimated as 79.1% at 2 years and 74.9% at 5 years. 
 
For survival analysis, we considered the association between the disease-specific 
survival and the Ann Arbour stage, IPI score, and age at the time of diagnosis (≤ or > 60 
years and ≤ or > 70 years . In our dataset, individualized Ann Arbour stage was not associated 
with prognosis (p=0.088) (Figure 12), whereas grouped Ann Arbour stage (stages I/II vs. 
III/IV) was associated with prognosis (p=0.015).  
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IPI score (p=0.005) and age at the time of diagnosis (≤ or > 60 years and ≤ or > 70 
years) were significantly associated with prognosis (p=0.006 and p=0.005, respectively) 
(Figures 13 and 14). Indeed, lower IPI score and age at diagnosis were associated with a 
better outcome.  
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Figure 12 - Analysis of disease-specific survival according to individualized or grouped Ann Arbour stage. 
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Figure 13 - Analysis of disease-specific survival according 
to grouped IPI score. 
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No difference in prognosis was observed concerning gender (p=0.154) (Figure 15). 
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Figure 14 - Analysis of disease-specific survival according to age (≤ or > 60 years and ≤ or > 70 years). 
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Figure 15 - Analysis of disease-specific survival according 
to gender. 
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3 – IMMUNOHISTOCHEMICAL PROFILE 
 
 The percentage of immunostained nuclei and the H-score were determined for each 
case and used to evaluate the immunoexpression profile. 
• H3K4me3 
For H3K4me3 epigenetic mark, Hscore varied between 4.1 and 276.2, with a median 
value of 157.1 (Figure 16). In statistical analysis of the distribution of Hscore of H3K4me3 
according to gender, age, Ann Arbour stage, transformation and IPI there were no 
statistically significant associations. We used Mann Whitney’s test for all the variables 
except for IPI score, in which Kruskal Wallis’ test was used (Table 7). 
 
Table 7 - Comparison between Hscore, clinical and pathological parameters. 
 P 
Gender 0.216 
Age (≤ or > 70 years) 0.118 
Ann Arbour Stage 0.148 
Transformation 0.536 
IPI 0.472 
 
The immunoexpression of H3K4me3 was not associated with disease-specific 
survival using either % Positivity and Hscore median (p=0.643 and p=0.917, respectively) 
or the 25th and 75th percentile for Hscore (p=0.978 and p=0.518, respectively) (Figures 18, 
19 and 20).  
 
 
 
 
 
 
 Figure 16 - Positive and negative nuclear immunostaining of H3K4me3. 
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• H3K27me3 
Concerning H3K27me3 epigenetic mark, Hscore varied between 38.6 and 247, with 
a median of 117.2 (Figure 17). In statistical analysis of the distribution of Hscore of 
H3K4me3 according to gender, age, Ann Arbour stage and transformation there were no 
statistically significant results except for IPI score (p = 0.041). We used Mann Whitney’s test 
for all the variables except for IPI score, in which Kruskal Wallis’ test was used (Table 8). 
 
Table 8 - Comparison between Hscore, clinical and pathological parameters. 
  P 
Gender 0.634 
Age (≤ or > 70 years) 0.530 
Ann Arbour Stage 0.094 
Transformation 0.422 
IPI 0.041 
 
The immunoexpression of H3K27me3 was not associated with disease-specific 
survival using either the % Positivity and Hscore median (p=0.979 and p=0.959, 
respectively) or the 25th and 75th percentile (p=0.291 and p=0.683), respectively) (Figures 
18, 19 and 20). 
 
Figure 17 - Positive and negative nuclear immunostaining of H3K27me3. 
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Figure 18 - Analysis of disease-specific survival by % Positivity, in the left panel and Hscore, on the right panel. 
The comparison is made using the median. 
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Figure 19 - Analysis of disease-specific survival by % Positivity, in the left panel and Hscore, on the 
right panel. The comparison is made using the 25th percentile. 
Figure 20 - Analysis of disease-specific survival by % Positivity, in the left panel and Hscore, on the 
right panel. The comparison is made using the 75th percentile. 
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Diffuse large B-cell lymphomas are a heterogeneous group of lymphoid neoplasms 
that have a wide range of clinical presentations, immunologic characteristics, genetical 
features and clinical outcomes in patients that experience standard therapy (8). It is important 
to emphasize the diversity of DLBCL as it must be taken into consideration when 
investigating new therapies (9, 27, 33). Currently, prognosis of patients with DLBCL is 
estimated using the clinical parameters of the International Prognostic Index (27). The 
predictive ability of IPI is, however, limited and estimating the risk that a DLBCL poses to 
an individual patient remains a challenging task. Thus, improved means of prognostication 
are critical to allow for individualized risk-adapted therapy. Likewise, development of 
predictive biomarkers will be essential to select appropriate patients for novel target 
approaches with the goal of achieving a personalized cancer care approach (33,47). Taking 
in consideration these principles and considering that altered patterns of histone 
modifications associated with EZH2 and MLL2 mutations occur in DLBCL (55, 58, 64, 68), we 
hypothesized that a quantitative evaluation of histone marks, specifically H3K4me3 and 
H3K27m3, might provide candidate prognostic biomarkers which might be used as ancillary 
tools for risk-stratification of DLBCL patients. 
This study was based in a consecutive series of 155 patients diagnosed with DLBCL 
and treated in IPO Porto between 2008 and 2013. The median age at diagnosis, 66 years, 
and the percentage of patients more than 70 years old (36,1%) are in accordance with 
published literature (11). However, the observed M/F ratio was 1/1.3, which is an inverse 
proportion compared to most published studies (1,2,14). There is no clear explanation for this 
finding, which might bias subsequent analyses. Nevertheless, gender is not considered a 
prognostic factor in DLBCL and, thus, we are confident that the bias, if it exists, it is likely to 
be negligible. Indeed, more relevant parameters including the distribution of IPI score 
(13.5%, 42.6% and 32.9%) and the proportion of patients with transformation/recurrence 
(40%) are similar to those of previous studies (27,1,5). Sample size, however, might account 
for some results, such as the lack of association of individualized Ann Arbour stage (i.e., 
stages I vs. II vs. III vs. IV), which was, however, disclosed when stages I/II and III/IV were 
lumped together. Moreover, and as expected, IPI score and age at the time of diagnosis 
(both ≤ or > 60 years and ≤ or > 70 years  were significantly associated with prognosis, 
providing indirect validation of this patient cohort. 
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The main goal of this study was to investigate the potential of quantitative H3K4me3 
and H3K27me3 immunoexpression as prognostic biomarker in DLBCL, which, to the best 
of our knowledge, has not been attempted before. The rationale for this approach was that 
the enzymes that catalyse H3K4me3 and H3K27me3, specifically MLL2 and EZH2, display 
altered activity in a proportion of DLCBL cases. Whereas the EZH2 activating mutations, 
which were found in up to 22% of DLCBL (55, 58, 64, 68), are deemed to increase H3K27me3, 
MLL2 inactivating mutations, occurring in 32% of DLBCL (80,81), are expected to decrease 
H3K4me3. Di- and trimethylation of H3K4 is linked to transcriptional activation and high 
levels of H3K4me3 trimethylation are associated with the promoters of actively transcribed 
genes (57-59). H3K27me3, on the other hand, is an epigenetic mark associated with 
transcriptional silencing by promoting a compact chromatin structure (57-59). Thus, both 
alterations might lead to inappropriate silencing of genes that are critical for the control of 
cell growth and proliferation. We expected that more aggressive DLCBL would associate 
with lower and/or higher H3K4me3 and H3K27me3 Hscore/percentage of immunostained 
cells, respectively. However, only a significant association between IPI and H3K27me3 
Hscore was found. Moreover, survival analysis did not disclose any association between 
quantitative H3K4me3 and H3K27me3 immunoexpression and patients’ outcome, although 
several cutoff values were tested (P25, median, P75). A previous study has shown an 
association between increased H3K27me3 and poor overall survival in DLBCL (83) and in 
other tumor models increased EZH2 expression has been associated with worse prognosis 
and an increase of invasion and tumour progression capacities (41). Nevertheless, it is 
noteworthy that the association observed between increased H3K27me3 expression and 
poor overall survival was restricted to non-GCB DLBCL patients (83). Our cohort includes 
both GCB and non-GCB DLBCL, which we did not discriminate owing to the lack of sufficient 
immunophenotypical information. Thus, a direct comparison between the two studies 
cannot be made. Moreover, our negative results might also derive from an insufficient 
sample size, not having statistical power to disclose the previously reported associations. It 
should also be recalled that the immunohistochemical assay used in our study provides a 
global estimate of H3K4me3 and H3K27me3 expression, which might not reflect important 
gene-specific silencing events, which we are not able to identify with this methodology. 
However, the selection of an immunohistochemical assay was based on the widespread 
availability of this technique in most Pathology labs, eventually facilitating translation into 
routine clinical practice. 
Several limitations of this study should be acknowledged. Firstly, and as previously 
stated, sample size may not be sufficient to ascertain a significant association between 
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H3K4me3 and H3K27me3 immunoexpression and prognosis. In some cases, information 
about prognosis factors (Ann Arbour Stage and IPI) was missing and this may negatively 
influence statistical analyses. Furthermore, the absence of discrimination of DLCBL 
according to the cell of origin, i.e., using the immunohistochemical assays for CD10, BCL6 
and MUM1 as surrogate markers to identify GCB and non-GCB subtypes, precluded a more 
precise and detailed evaluation of the potential prognostic value of the epigenetic marks 
tested. Nevertheless, an important and innovative feature of this study must also be 
emphasized: the use of quantification of immunoexpression by means of a digital image 
assisted system (GenASIs™) which is able to provide more reliable and reproducible 
results. This type of approach is seldom used in routine pathological practice but its use 
should be encouraged to increase the reliability of several immunohistochemical 
parameters that are currently used to assist in therapeutic decision.  
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Considering our results, we may conclude that in our patient cohort, that globally 
may be considered representative of DLCBL patients, quantitative H3K4me3 and 
H3K27me3 immunoexpression were not disclosed as candidate prognostic biomarkers. 
The next steps of this work have already been defined. First, the cohort will be 
increased with the addition of more cases, to allow for a more powerful statistical analysis. 
Secondly, discrimination of GCB and non-GCB subtypes will be accomplished using 
immunohistochemistry assays, setting the basis for a more in-depth evaluation of H3K4me3 
and H3K27me3 prognostic value. 
From a biological standpoint, mutational analysis of the genes encoding for EZH2 
and MLL2 and its correlation with H3K4me3 and H3K27me3 immunoexpression would be 
very interesting and eventually afford a functional basis for your findings. In the same vein, 
the identification of specific genes downregulated due to decreased H3K4me3 and/or 
increased H3K27me3 might also provide new targets for therapeutic intervention, and 
contribute to improve survival and quality of life of patients afflicted by DLBCL. 
A better understanding of the mechanism leading to B-cell lymphomagenesis was 
brought by recently discovered epigenetic alterations, although more studies are needed to 
better clarify their role and clinical relevance. Because several epigenetic alterations are 
also putative therapeutic targets, research in this field might be envisaged as promising and 
should be stimulated. 
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